Company Analysis
Sign in

Burning Rock Biotech Limited (BNR)

Nasdaq: BNR · Services-Medical Laboratories · Guangzhou, Guangdong, CN · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.1
◀ Past 5.2● Present 4.9▶ Future 5.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueCN¥540M+4.6%
Net income-CN¥55.3M+84.0%
Earnings per sharen/a
Operating cash flow-CN¥28.4M+69.2%
CashCN¥481M-7.9%
DebtCN¥1.7M
Shareholders’ equityCN¥535M-7.8%
Shares, dilutedn/a
Return on equity-10.3%
The recordfrom its filings
Filings in 202614
Newest filingSep 10 · 6-K
Annual reportApr 28, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$11.6M
Patents granted1
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in CNY. Nothing here is a forecast.

News

Jul 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Apr 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton BNR · research, not advice